|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||N/A - N/A|
|52 Week Range||undefined - undefined|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Pfizer Inc. (PFE) today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved NIVESTYM™ (filgrastim-aafi), a biosimilar to Neupogen1 (filgrastim), for all eligible indications of the reference product.
LONDON, UK / ACCESSWIRE / July 19, 2018 / If you want access to our free earnings report on Johnson & Johnson (NYSE: JNJ) ("JNJ”"), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=JNJ. The Company reported its financial results on July 17, 2018, for the second quarter of the fiscal year 2018, ended June 30, 2018. The Company surpassed analysts’ estimates for earnings and revenues in Q2 FY18.
NEW YORK, NY / ACCESSWIRE / July 18, 2018 / Johnson & Johnson saw a pop after announcing second quarter results and vowing to appeal a court order last week that ordered the company to pay a whopping $4.69 billion to nearly two dozen women who alleged the company's talc products contained asbestos and caused them to develop ovarian cancer. Shares of Avid Bioservices also saw big gains after announcing a new CFO. Johnson & Johnson shares saw a gain of 3.54% by the close on Tuesday on trading volume nearly double compared to usual.
Pfizer Inc.(PFE) and Eli Lilly and Company (LLY) today announced that a 16-week Phase 3 study in patients with osteoarthritis (OA) pain evaluating subcutaneous administration of tanezumab, an investigational humanized monoclonal antibody, met all three co-primary endpoints. The study demonstrated that patients who received two doses of tanezumab separated by eight weeks experienced a statistically significant improvement in pain, physical function and the patients’ overall assessment of their OA, compared to those receiving placebo. Tanezumab is part of an investigational class of pain medications known as nerve growth factor (NGF) inhibitors and in addition to OA pain, is being evaluated for chronic low back pain (CLBP) and cancer pain (due to bone metastases).
2018 Second-Quarter Sales of $20.8 Billion Increased 10.6% versus 2017 2018 Second-Quarter EPS was $1.45 2018 Adjusted Second-Quarter EPS of $2.10 increased 14.8%* Accelerating Operational Sales Growth ...
NEW YORK, NY / ACCESSWIRE / July 17, 2018 / Johnson & Johnson (NYSE: JNJ ) will be discussing their earnings results in their Q2 Earnings Call to be held on July 17, 2018 at 8:30 AM Eastern Time. To listen ...
NEW BRUNSWICK, N.J., July 16, 2018 /PRNewswire/ -- Johnson & Johnson (JNJ) today announced that its Board of Directors has declared a cash dividend for the third quarter of 2018 of $0.90 per share on the company's common stock. The dividend is payable on September 11, 2018 to shareholders of record at the close of business on August 28, 2018. At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress.
Pfizer Inc. (PFE) and Spark Therapeutics (ONCE) announced today that Pfizer initiated a Phase 3 open-label, multi-center, lead-in study (NCT03587116) to evaluate the efficacy and safety of current factor IX prophylaxis replacement therapy in the usual care setting. The factor IX prophylaxis efficacy data obtained in the lead-in study will serve as the within-subject control group for those patients that enroll into the next part of the Phase 3 study, which will evaluate the investigational gene therapy fidanacogene elaparvovec for the treatment of hemophilia B. The interventional portion of this pivotal Phase 3 study will enroll patients who have completed at least six months in the lead-in study.
NEW YORK, NY / ACCESSWIRE / July 16, 2018 / Johnson & Johnson shares saw a drop on Friday as traders reacted to last week’s court decision that the company owes $4.69 billion to 22 women over its talc-based products allegedly causing them cancer. The company is vehement on appealing the court order. Biocept shares were skyrocketing on an announcement that it has entered into an agreement with Alliance Global FZ to market and distribute liquid biopsy testing in the Middle East, Southeast Asia, and the Africa region.
Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Pfizer Inc. (PFE) today announced the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) for XTANDI® (enzalutamide), following FDA Priority Review designation, based on results from the Phase 3 PROSPER trial. The FDA action broadens the indication for XTANDI to men with castration-resistant prostate cancer (CRPC), now including men with non-metastatic CRPC. This approval makes XTANDI the first and only oral medication FDA-approved for both non-metastatic and metastatic CRPC.
First and Only Oral Treatment FDA-Approved for Both Non-Metastatic and Metastatic CRPC TOKYO and NEW YORK , July 13, 2018 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa ...
NEW YORK, NY / ACCESSWIRE / July 13, 2018 / U.S. markets made it in the green on Thursday, pushed higher by rally in information technology and telecom stocks, covering continued uncertainty over trade ...
NEW BRUNSWICK, N.J., July 12, 2018 /PRNewswire/ -- Johnson & Johnson (JNJ) issued the following statement regarding today's verdict in the St. Louis court. "Johnson & Johnson is deeply disappointed in the verdict, which was the product of a fundamentally unfair process that allowed plaintiffs to present a group of 22 women, most of whom had no connection to Missouri, in a single case all alleging that they developed ovarian cancer.
The six-man, six-woman jury in Judge Rex M. Burlison's 22nd Judicial Circuit Court in St. Louis heard six weeks of testimony and deliberated eight hours before returning the verdict. While there have been other trials in which juries have determined that talc products contained asbestos and caused mesothelioma cancer, this case marks the first talc/asbestos-induced ovarian cancer verdict in the United States.
NEW YORK, NY / ACCESSWIRE / July 12, 2018 / Shares of Achieve Life Sciences exploded on Wednesday after the company announced the advancement of the Cytisine Development Program after its meeting with ...
Following an extensive discussion with President Trump today, Pfizer’s Chairman and CEO Ian Read announced that it will defer the company’s price increases that were effective on July 1 to give the president an opportunity to work on his blueprint to strengthen the healthcare system and provide more access for patients. “Pfizer shares the President’s concern for patients and commitment to providing affordable access to the medicines they need,” said Ian Read. “The most fundamental way the biopharmaceutical industry creates value is by discovering innovative medicines that help people live longer, healthier, more productive lives.
NEW YORK, NY / ACCESSWIRE / July 10, 2018 / Shares of Pfizer may have ended up flat yesterday but it wasn't the greatest news day for the pharmaceutical giant. President Trump took to Twitter to raise his concerns on the company as well as other drug makers for recently increasing prices. Shares of Benitec Biopharma was a big winner and even hit a new high after announcing a licensing agreement with Axovant.
On Thursday, July 05, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. All sectors ended Thursday's trading session in bullish territories. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Drug Manufacturers - Major equities this morning: Heron Therapeutics Inc. (NASDAQ: HRTX), Immune Pharmaceuticals Inc. (NASDAQ: IMNP), Johnson & Johnson (NYSE: JNJ), and Sanofi (NYSE: SNY).
Pfizer Inc. (PFE) announced today that the European Commission (EC) has approved XELJANZ® (tofacitinib citrate) 5 mg twice daily (BID) in combination with methotrexate (MTX) for the treatment of active psoriatic arthritis (PsA) in adult patients who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug (DMARD) therapy.1 XELJANZ is the first and only oral Janus kinase (JAK) inhibitor to be approved in the European Union (EU) for the treatment of adults with active PsA. “People living with psoriatic arthritis may experience a variety of symptoms, making the condition particularly difficult to diagnose and treat,” said Angela Lukin, Regional President, Inflammation and Immunology, Pfizer.
The board of directors of Pfizer Inc. today declared a 34-cent third-quarter 2018 dividend on the company’s common stock, payable September 4, 2018, to shareholders of record at the close of business on August 3, 2018. The third-quarter 2018 cash dividend will be the 319th consecutive quarterly dividend paid by Pfizer. At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives.
Pfizer Inc. (PFE) today announced that the U.S. Food and Drug Administration (FDA) accepted the company’s New Drug Application and granted Priority Review designation for glasdegib, an investigational oral smoothened (SMO) inhibitor, being evaluated for the treatment of adult patients with previously untreated acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC), a type of chemotherapy. “Patients with acute myeloid leukemia who are ineligible for intensive chemotherapy are in critical need of new treatment options to improve their overall survival,” said Mace Rothenberg, M.D., chief development officer, Oncology, Pfizer Global Product Development.
TITUSVILLE, N.J., June 26, 2018 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson and Johnson & Johnson Innovation LLC are joining with Mental Health America, OneMind, PeaceLove and other leading mental health and arts organizations to leverage the power of artistic creation to break down stigma about mental illnesses and build greater empathy and understanding. Champions of Science: The Art of Ending Stigma, a new global project, encourages all people to share artistic expressions about mental illnesses and the importance of overcoming stigma, while also educating about the biological basis of these diseases.
Stock Research Monitor: GSK, MRK, and NVS LONDON, UK / ACCESSWIRE / June 26, 2018 / If you want a free Stock Review on PFE sign up now at www.wallstequities.com/registration . On Monday, benchmark US indices ...
Pfizer today announced overall survival results from the Phase 3 PALOMA-3 trial, which evaluated IBRANCE® in combination with fulvestrant compared to placebo plus fulvestrant in women with hormone receptor-positive , human epidermal growth factor receptor 2-negative metastatic breast cancer whose disease has progressed after prior endocrine therapy.